Exscientia plc (Nasdaq: EXAI), a frontrunner in AI-driven precision medicine, has officially announced a significant leadership adjustment and the submissi...
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment last...
Under a collaboration with LGC Biosearch TechnologiesTM, RevoluGen has coupled its Fire Monkey chemistry with LGC magnetic beads and LGC oKtopureTM liquid ...
Strategic collaboration to open a new chapter in the field of molecular diagnostics that aspires to 'a world free from all diseases and future pandemics'...
ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring. ProteinLogic ImmiPrint® diagnostic patt...
The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cov...
Under the partnership with Pfizer, Ultromics will research and pursue FDA clearance for its EchoGo® Amyloidosis algorithm that already has Breakthrough...
Illumina Ventures Labs is part of Illumina Ventures, the premier genomics and precision health venture firm supporting early-stage companies transforming h...
Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this...
Fortrea , a leading global contract research organization (CRO), today announced an industry partnership with founding members Veeva Systems Inc., a l...
Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approxi...
Roivant (Nasdaq: ROIV) announced the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upf...
RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) dedicated to developing therapies for patients w...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...
© 2024 Biopharma Boardroom. All Rights Reserved.
